ConductScience.org, home

Paper39748838

Alzheimer's disease drug development in an evolving therapeutic landscape.

Weninger S and 8 others. Alzheimers Dement (N Y), 2024. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Alzheimer's disease drug development in an evolving therapeutic landscape. Papers, record 39748838. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39748838

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Alzheimer's disease drug development in an evolving therapeutic landscape.
PubMed
Journal
Alzheimers Dement (N Y)
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.61, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Weninger SStacie
2Irizarry MCMichael C
3Fleisher ASAdam S
4León TTeresa
5Maruff PPaul
6Miller DSDavid S
7Seleri SSheila
8Carrillo MCMaria C
9Weber CJChristopher J

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130410033Multiple sclerosis.Nat Rev Dis Primers2018https://conductscience.org/library/papers/30410033PubMed
234289882The informed road map to prevention of Alzheimer Disease: A call to arms.Mol Neurodegener2021https://conductscience.org/library/papers/34289882PubMed
333720637Donanemab in Early Alzheimer's Disease.N Engl J Med2021https://conductscience.org/library/papers/33720637PubMed
424928124Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.Neurology2014https://conductscience.org/library/papers/24928124PubMed
536449413Lecanemab in Early Alzheimer's Disease.N Engl J Med2023https://conductscience.org/library/papers/36449413PubMed
633865446A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.Alzheimers Res Ther2021https://conductscience.org/library/papers/33865446PubMed
734331706"Real world" eligibility for aducanumab.J Am Geriatr Soc2021https://conductscience.org/library/papers/34331706PubMed
835542991Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.J Prev Alzheimers Dis2022https://conductscience.org/library/papers/35542991PubMed
928767357Evidence for Health Decision Making - Beyond Randomized, Controlled Trials.N Engl J Med2017https://conductscience.org/library/papers/28767357PubMed
1033043108Advancing combination therapy for Alzheimer's disease.Alzheimers Dement (N Y)2020https://conductscience.org/library/papers/33043108PubMed
1132161412A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.Nat Med2020https://conductscience.org/library/papers/32161412PubMed
1234155411A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.Nat Med2021https://conductscience.org/library/papers/34155411PubMed
1337251912Alzheimer's disease drug development pipeline: 2023.Alzheimers Dement (N Y)2023https://conductscience.org/library/papers/37251912PubMed
1436655336Anti-amyloid antibody therapies in Alzheimer's disease.Brain2023https://conductscience.org/library/papers/36655336PubMed
1539350367Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.J Prev Alzheimers Dis2024https://conductscience.org/library/papers/39350367PubMed
1636730056Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.Brain2023https://conductscience.org/library/papers/36730056PubMed
1737586881Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.Neurology2023https://conductscience.org/library/papers/37586881PubMed
1821211070Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.Alzheimers Res Ther2011https://conductscience.org/library/papers/21211070PubMed
1937097366Randomized Trials vs Real-world Evidence: How Can Both Inform Decision-making?JAMA2023https://conductscience.org/library/papers/37097366PubMed
2039748838Alzheimer's disease drug development in an evolving therapeutic landscape.Alzheimers Dement (N Y)2024https://conductscience.org/library/papers/39748838PubMed

See all 25 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42382756Calibrating microglia states in Alzheimer's disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies.Front Immunol2026https://conductscience.org/library/papers/42382756PubMed
42118396From Molecular Networks to Medicines: Targeting Complexity in Alzheimer's Disease (AD) Therapy.Mol Neurobiol2026https://conductscience.org/library/papers/42118396PubMed
40529145Integrating genetic and immune profiles for personalized immunotherapy in Alzheimer's disease.Front Med (Lausanne)2025https://conductscience.org/library/papers/40529145PubMed
39748838Alzheimer's disease drug development in an evolving therapeutic landscape.Alzheimers Dement (N Y)2024https://conductscience.org/library/papers/39748838PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39748838

GET https://conductscience.org/api/papers/v1/39748838/references?page=2